Immutrin secures £65m Series A for amyloid-removing heart therapy
Immutrin, a UK biotech, has raised £65m (€75m) in Series A funding for a pioneering antibody designed to remove pre-existing amyloid deposits in amyloidosis.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1527 entries already.
Entries by Thomas Gabrielczyk
Organoids: new Roche research centre in Basel will focus on alternative model systems
/in News/by Thomas GabrielczykAnimal testing or organoids—this question is increasingly being answered in favour of organoids. Yet robust model systems still require further research and, crucially, validation. More large pharmaceutical companies are now pursuing this goal, whether by acquiring relevant start-ups or by establishing their own research centres, as Roche has just done in Basel.
Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics
/in News/by Thomas GabrielczykSanofi is expanding its immunology toolbox: The French pharma pays up to US$1.2bn for worldwide exclusive rights to Kali Therapeutics’ next-generation tri-specific T-cell engager targeting B cell-mediated autoimmune diseases.
Dutch biotech Laigo Bio bags €17m in oversubscribed seed round
/in News/by Thomas GabrielczykMembrane protein degradation specialist Laigo Bio has completed the final close of its €17m (US$18.5m) seed financing. Funds will go towards the oncology and auto-immunity programmes based on the company’s bispecific antibody platform for hard-to-treat targets.
Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy
/in News/by Thomas GabrielczykNovartis is pressing ahead with its aggressive expansion strategy in oncology, striking again: the Basel-based group is acquiring a novel PI3Kalpha inhibitor from Synnovation Therapeutics for up to USD 3 billion.
Swiss Roche builds its own AI factory with NVIDIA – with Genentech in California
/in News/by Thomas GabrielczykThe Basel-based pharmaceutical group Roche is pressing ahead with its digital strategy and setting new benchmarks for the industry. Together with NVIDIA, the company is building an “AI factory” that will become the largest computing infrastructure ever announced by a pharma company. In the race among pharma majors, Roche has now overtaken the supercomputer recently unveiled by Eli Lilly.
Mestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinic
/in News/by Thomas GabrielczykUK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares to start its first clinical trial in cancer in mid-2026. The new financing brings total capital committed to the Cambridge-based company to more than $95 million, following its $11 million launch round in April 2021 and a seed extension that took total seed financing to $45 million in August 2021.
Delivering drugs into cells: Seed funding for German iDEL and its ‘wonder shuttle’
/in News/by Thomas GabrielczykThe new Dortmund-based biotech iDEL Therapeutics has launched with a €9 million seed round to develop a new class of cancer therapies. The financing was led by BiomedVC, with participation from NRW.Venture, Gründerfonds Ruhr and the KHAN Technology Transfer Fund II.
Ternary Therapeutics lands €4.1M seed round to push AI-designed molecular glues into inflammatory disease
/in News/by Thomas GabrielczykLondon-based Ternary Therapeutics has raised a €4.1 million seed round to expand its platform for designing molecular glue drugs, with Paris-based VC daphni leading the financing alongside Pace Ventures, i&i Biotech Fund and Future Planet Capital.
Owkin spins out AI diagnostics startup Waiv with $33M financing
/in News/by Thomas GabrielczykFrench AI biotech Owkin has spun out its diagnostics division as a new company, Waiv, raising $33 million in financing led by OTB Ventures and Alpha Intelligence Capital to scale AI-powered precision testing.